S26 - MS and CNS Inflammatory Disease: Clinical Considerations II
| Event Time: | Tuesday May 7, 2019 1:00 pm to 3:00 pm |
| Topic(s): | MS and CNS Inflammatory Disease |
| Director(s): | |
| Description: | |
| Completion Message: | |
| CME Credits: | 2 |
| Core Competencies: |
| Start/End Time | Title | Faculty |
|---|---|---|
| 2:40 PM - 3:00 PM | Q&A Panel with Authors | Faculty |
| Speaker | Disclosure |
|---|
| Start Time | Pub. | Title | Presenter |
|---|---|---|---|
| 1:00 PM | 001 | Serum Neurofilament Light (sNfL) for Disease Prognosis and Treatment Monitoring in Multiple Sclerosis Patients:Towards Implementation into Clinical Care |
Disclosure: Dr. Calabresi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with consulting fees from Biogen and Disarm Therapeutics. Dr. Calabresi has received personal compensation in an editorial capacity for The Journal of Clinical Investigation. Dr. Calabresi has received research support from research support to JHU from Annexon Biosciences, Biogen, MedImmune, and Novartis.
|
| 1:00 PM | 002 | Timing of MRI Cervical Spine and Finding Asymptomatic T2 Hyperintensities in Multiple Sclerosis Patients |
Disclosure: Dr. Malik has nothing to disclose.
|
| 1:00 PM | 003 | Trends in the use of Highly Effective Disease Modifying Treatments in Multiple Sclerosis over 12 years across 10 Sites |
Disclosure: Dr. McGinley has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi Genzyme, Genentech. Dr. McGinley has received research support from Novartis.
|
| 1:00 PM | 004 | Functional Characterization of Reappearing B cells After Anti-CD20 Mediated B cell Depletion in Two Animal Models of Multiple Sclerosis |
Disclosure: Dr. Häusler has nothing to disclose.
|
| 1:00 PM | 005 | Spontaneous Intracerebral Hemorrhage During Administration of Alemtuzumab for Multiple Sclerosis: A Case Series |
Disclosure: Dr. Azevedo has received personal compensation for consulting serving on a scientific advisory board speaking or other activities with Sanofi-Genzyme Genentech Novartis Biogen Idec.
|
| 1:00 PM | 006 | Reduced risk of progressive multifocal leukoencephalopathy (PML) associated with natalizumab extended interval dosing (EID): updated analysis of the TOUCH® Prescribing Program database |
Disclosure: Dr. Zhovtis Ryerson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Dr. Zhovtis Ryerson has received personal compensation for serving on speaker bureau for Biogen, Teva, Genentech and advisory board for Biogen and Celgene. Dr. Zhovtis Ryerson has received research support from Biogen.
|
| 1:00 PM | 007 | Serious Infections in Two Large US and Swedish Rituximab-treated Multiple Sclerosis Cohorts |
Disclosure: Dr. Langer-Gould has nothing to disclose.
|
| 1:00 PM | 008 | Cladribine to treat Relapsing and Progressive Multiple Sclerosis - experience in >200 patients |
Disclosure: Dr. De Trane has nothing to disclose.
|
| 1:00 PM | 009 | Longitudinal study of symptom botheration in Multiple Sclerosis patients |
Disclosure: Dr. Kister has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with ad board consulting for Biogen. Dr. Kister has received research support from research fundings from Biogen, Sanofi Genzyme, and Genentech.
|
Ready to register for the 2019 AAN Annual Meeting?
Related Courses
| 7:00 AM-9:00 AM |
|---|
|
C7 -
Clinical Pearls in Autoimmune Neurology: Real World Cases
Stacey Clardy MD, PhD |
| 9:30 AM-11:30 AM |
|
C19 -
Multiple Sclerosis Overview I: Clinical Pearls
Mary Willis MD |
| 1:30 PM-3:30 PM |
|
C29 -
Multiple Sclerosis Overview II: Clinical Advances
Scott Newsome DO, FAAN |
| 7:00 AM-9:00 AM |
|---|
|
C44 -
Multiple Sclerosis Therapy: Symptom Management
Andrew Solomon MD, FAAN |
| 9:15 AM-12:00 PM |
|
Presidential Plenary Session
Natalia Rost MD, MPH, FAAN, FAHA |
| 11:30 AM-6:30 PM |
|
P1 -
Poster Session 1
|
| 1:00 PM-3:00 PM |
|
C49 -
Neurology Update I: Multiple Sclerosis, Sleep, and Neuromuscular Disease
Ralph Jozefowicz MD, FAAN, Adam Quick MD |
|
C56 -
Multiple Sclerosis Therapy: Disease-modifying Treatment I
Scott Newsome DO, FAAN |
|
S6 -
MS and CNS Inflammatory Disease: Clinical Considerations I
|
| 3:30 PM-5:30 PM |
|
C73 -
Multiple Sclerosis Therapy: Disease-modifying Treatment II
John Rose MD, FAAN |
| 7:00 AM-9:00 AM |
|---|
|
C86 -
Neuromyelitis Optica Spectrum Disorders
Dean Wingerchuk MD, FAAN |
| 9:15 AM-12:00 PM |
|
Contemporary Clinical Issues Plenary Session
Randolph Marshall MD, FAAN |
| 11:30 AM-6:30 PM |
|
P2 -
Poster Session 2
|
| 1:00 PM-3:00 PM |
|
C100 -
Esclerosis Múltiple y Otras Enfermedades Inflamatorias Desmielinizantes y Autoinmunes del Sistema Nervioso Central (MS and Other Demyelinating Inflammatory and Autoimmune Central Nervous System Disorders)
Lilyana Amezcua MD, FAAN |
|
S12 -
Progressive Multiple Sclerosis
|
| 3:30 PM-5:30 PM |
|
S19 -
Child Neurology: Updates in Autism, Migraine, MS, and Stroke
|
| 7:00 AM-9:00 AM |
|---|
|
C130 -
Diagnostic Pearls in Myelitis: a Case-based Approach
Eoin Flanagan MBBCh |
| 9:15 AM-11:30 AM |
|
Clinical Trials Plenary Session
Deborah Hall MD, PhD, FAAN, Holly Hinson MD, MCR, FAAN |
| 11:30 AM-6:30 PM |
|
P3 -
Poster Session 3
|
| 1:00 PM-3:00 PM |
|
C142 -
Autoimmune Neurology I Basics and Beyond: Autoimmune Encephalitis and Paraneoplastic Neurological Syndromes of the CNS and PNS
Stacey Clardy MD, PhD |
|
N3 -
Neuroscience in the Clinic: Stem Cells
Paul George MD, PhD, MSE, Antonio Omuro MD |
| 3:30 PM-5:30 PM |
|
C160 -
Autoimmune Neurology II Advanced: Autoimmune Encephalitis at the Frontiers of Neuroscience
Eoin Flanagan MBBCh |
|
S31 -
MS and CNS Inflammatory Disease: Imaging
|
| 9:15 AM-11:30 AM |
|---|
|
Frontiers in Neuroscience Plenary Session
Paul George MD, PhD, MSE |
| 11:30 AM-6:30 PM |
|
P4 -
Poster Session 4
|
| 1:00 PM-3:00 PM |
|
C181 -
Treatment of Pediatric Multiple Sclerosis in the Current Era
Brenda Banwell MD, FAAN |
|
S37 -
MS Biomarkers
|
| 3:30 PM-5:30 PM |
|
Presentation of the John Dystel Prize for Multiple Sclerosis Research
|
| 3:45 PM-4:15 PM |
|
Update on the Complementary Therapies for MS: An Evidence-based Review
Vijayshree Yadav MD, FAAN |
| 11:30 AM-6:30 PM |
|---|
|
P5 -
Poster Session 5
|
| 12:00 PM-12:45 PM |
|
A "How to and Why" of the Shared Medical Appointments: A Way to Meet the Needs of the Patient and Provider While Maximizing Clinical Time
Mary Rensel MD, FAAN, Nancy Isenberg MD, MPH, FAAN |
| 1:00 PM-3:00 PM |
|
C226 -
Neuro-rheumatology: Neurological Manifestations of Systemic Inflammatory and Autoimmune Disease I
Jeffrey Gelfand MD, MAS, FAAN |
|
S49 -
MS Epidemiology and Risk Stratification
|
| 3:30 PM-5:30 PM |
|
C236 -
Neuro-rheumatology: Neurological Manifestations of Systemic Inflammatory and Autoimmune Disease II
Jeffrey Gelfand MD, MAS, FAAN |
|
S55 -
MS Basic Science
|
| 7:00 AM-9:00 AM |
|---|
|
C248 -
Multiple Sclerosis in the Trenches: Controversy and Consensus in Clinical Decision-Making
Aaron Miller MD, FAAN |
| 9:15 AM-11:30 AM |
|
Neurology Year in Review Plenary Session
Martinson Arnan MD |
| 1:00 PM-3:00 PM |
|
S56 -
MS Trials and Treatment
|
| 3:30 PM-4:30 PM |
|
C257 -
Education Blitz: Evolution of Autoimmune Neurology
Steven Vernino MD, PhD, FAAN |
|
C258 -
Education Blitz: Multiple Sclerosis
Stephen Krieger MD, FAAN |